EU/3/19/2160
About
On 29 May 2019, orphan designation (EU/3/19/2160) was granted by the European Commission to RHEACELL GmbH & Co. KG, Germany, for allogeneic skin-derived ABCB5-positive mesenchymal stem cells (also known as allo-APZ2-EB) for the treatment of epidermolysis bullosa.
Key facts
Active substance |
Allogeneic skin-derived ABCB5-positive mesenchymal stem cells
|
Disease / condition |
Treatment of epidermolysis bullosa
|
Date of first decision |
29/05/2019
|
Outcome |
Positive
|
EU designation number |
EU/3/19/2160
|
Sponsor's contact details
RHEACELL GmbH & Co. KG
Im Neuenheimer Feld 517
69120 Heidelberg
Germany
Tel. +49 6221 718330
E-mail: office@rheacell.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: